Atara Biotherapeutics (NASDAQ: ATRA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 22.22 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $4.25 million which missed the analyst consensus estimate of $11.55 million by 63.19 percent. This is a 1.82K percent increase over sales of $221.00 thousand the same period last year.